Number of the records: 1
Lipophosphonoxins of second generation, and their use
- 1.
SYSNO ASEP 0519526 Document Type P - Patent R&D Document Type Patent or other outcome protected by special legislation Title Lipophosphonoxins of second generation, and their use Author(s) Rejman, Dominik (UOCHB-X) RID, ORCID
Pohl, Radek (UOCHB-X) RID, ORCID
Zborníková, Eva (UOCHB-X) RID, ORCID
Krásný, Libor (MBU-M) RID, ORCID
Látal, T. (CZ)
Kolář, M. (CZ)Year of issue 2019 Possible third party use of the result A - Pro využití výsledku jiným subjektem je vždy nutné nabytí licence Royalty requested A - Poskytovatel licence požaduje licenční poplatek Patent no. or utility model no. or industrial design no. AU2017257061 Date of the patent acceptance 07.03.2019 Name of the patent owner Ústav organické chemie a biochemie AV ČR, v. v. i. - Mikrobiologický ústav AV ČR, v. v. i. - TRIOS, spol. s r. o Code of the issuer name AU001 - IP Australia Phillip ACT Current use A - Pouze udělený (dosud nevyužívaný) patent nebo patent využívaný jeho vlastníkem Language eng - English Keywords antibacterial ; lipophosphonoxin ; chemotherapeutic Subject RIV FN - Epidemiology, Contagious Diseases ; Clinical Immunology OECD category Medicinal chemistry R&D Projects TA02010035 GA TA ČR - Technology Agency of the Czech Republic (TA ČR) Institutional support UOCHB-X - RVO:61388963 ; MBU-M - RVO:61388971 Annotation Lipophosphonoxins of general Formula I are described here, wherein R1 is C8-C22, preferably C10-C18 and more preferably C12-C16 alkyl, or hexadecyloxypropyl, tetradecyloxypropyl, tetradecyloxyethyl or hexadecyloxyethyl, R2 is uracil, thymine, or cytosine, R3 is selected from a group which contains compounds of general formulas II and III, wherein R4 is H, CH2OH or CH2NH2, R5 is H, OH or NH2, R6 is H, OH or NH2, R7 is H, CH2OH or CH2NH2, wherein at least one of the groups R5 and R6 must be NH2 or one of the groups R4 and R7 must be CH2NH2. R8 is H, CH2OH or CH2NH2, R9 is H, OH or NH2, R10 is H, OH or NH2, R11 is H, OH or NH2, R12 is H, CH2OH or CH2NH2, wherein at least one of the groups R9, R10 and R11 must be NH2 or one of the groups R8 a R12 must be CH2NH2. R13 is NH2 or NH-CH(NH2)NH, R14 is NH2 or NH-CH(NH2)NH, R15 is NH2 or NH-CH(NH2)NH, R16 is NH2 or NH-CH(NH2)NH. Further, diastereomers and mixtures of diastereomers of compounds of general formula I and the corresponding pharmaceutically acceptable salts and/or hydrates are described. The compounds of general formula I are useful as antibacterial agents or active ingredients in disinfectants, and/or of selective in vitro culture media. Workplace Institute of Organic Chemistry and Biochemistry Contact asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Viktorie Chládková, Tel.: 232 002 434 Year of Publishing 2020 Electronic address https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20190307&DB=&locale=en_EP&CC=AU&NR=2017257061B2&KC=B2&ND=5#
Number of the records: 1